Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Mohammed W. Badri: Are We Doing Enough to Prevent Life-Threatening Bleeds in Children? 
Mohammed W. Badri/LinkedIn
Jul 20, 2026, 21:10

Mohammed W. Badri: Are We Doing Enough to Prevent Life-Threatening Bleeds in Children? 

Mohammed W. Badri, 6th year medical Student at University of Basrah – college of medicine, shared a post on LinkedIn:

“Are we doing enough to prevent life-threatening bleeds in children?

Last Tuesday at Basrah Speciality Children Hospital, I stood in front of my colleagues to present on a topic where a single mathematical miscalculation can change a child’s life: Clotting Factors Therapy.

Managing pediatric hemostasis isn’t just about giving a medication; it’s a high-stakes race against time.

When a child with severe Hemophilia comes in, every second counts. But the real challenge isn’t just treating the bleed—it’s what happens when the body fights back.

Here is what every healthcare professional and medical student needs to keep on their radar:

  1. The ‘Inhibitor’ Nightmare: The biggest barrier we face isn’t the deficiency itself, but when the patient’s immune system develops neutralizing antibodies (inhibitors) against Factor VIII or IX. It completely shatters the standard treatment plan.
  2. Precision Dosing over Guesswork: Target raises must be calculated dynamically (35-50% for standard bleeds, but strictly 100% for life-threatening ones like intracranial or GI bleeds).
  3. The Subcutaneous Shift: The traditional reliance on constant, painful IV pushes is shifting. Modern non-factor innovations like Emicizumab are completely redefining prophylaxis, especially for patients battling active inhibitors.

As medical providers, early recognition and switching from non-specific options to targeted factor replacement is what truly saves lives.

I have attached the full clinical presentation slides below. It breaks down the entire coagulation cascade, exact dosing formulas, and practical inhibitor management protocols.

If you are in the medical field, save this post for your next clinical rotation, and let’s discuss in the comments:

How is your center currently tackling the challenge of factor inhibitor development? ”

Mohammed W. Badri

Stay updated with Hemostasis Today.

Antibodies Basrah Speciality Children Hospital bleeding disorders Blood Clotting Factors Therapy Emicizumab Factor IX Factor VIII GI Bleeding Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today Medicine Mohammed W. Badri Pediatric Hemostasis
NewsFeed